Compare · ADIL vs JNJ
ADIL vs JNJ
Side-by-side comparison of Adial Pharmaceuticals Inc (ADIL) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADIL and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $452.25B, about 10042.2x ADIL ($45.0M).
- Over the past year, ADIL is down 91.0% and JNJ is up 46.5% - JNJ leads by 137.4 points.
- JNJ has been more active in the news (13 items in the past 4 weeks vs 8 for ADIL).
- JNJ has more recent analyst coverage (25 ratings vs 3 for ADIL).
- Company
- Adial Pharmaceuticals Inc
- Johnson & Johnson
- Price
- $1.56-1.27%
- $227.47-1.37%
- Market cap
- $45.0M
- $452.25B
- 1M return
- -10.60%
- -5.19%
- 1Y return
- -90.96%
- +46.49%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 8
- 13
- Recent ratings
- 3
- 25
Adial Pharmaceuticals Inc
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in phase 3 clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Charlottesville, Virginia.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest ADIL
- Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial
- SEC Form 4 filed by Anderson J. Kermit
- Adial Pharmaceuticals Inc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SEC Form 4 filed by Goodman Tony
- SEC Form 4 filed by Shah Vinay
- SEC Form 4 filed by Schuyler Kevin
- SEC Form 4 filed by Claiborne Cary J
- SEC Form 4 filed by Gilliland Robertson H.
- Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans
- Adial Pharmaceuticals Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest JNJ
- SEC Form 10-Q filed by Johnson & Johnson
- IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)
- Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
- Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026
- The Infrastructure Play Hiding in Plain Sight Across Cardiac Care
- Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference
- Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%
- Johnson & Johnson reports Q1 2026 results, raises 2026 outlook
- Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision